Literature DB >> 12393409

Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma.

Iwona Wlodarska1, Peet Nooyen, Brigitte Maes, José I Martin-Subero, Reiner Siebert, Patrick Pauwels, Chris De Wolf-Peeters, Anne Hagemeijer.   

Abstract

We studied the genomic status of BCL6 in 23 cases of nodular lymphocyte predominance Hodgkin lymphoma (NLPHL) and 40 cases of classical Hodgkin lymphoma (cHL), using dual-color interphase fluorescence in situ hybridization (FISH). The BCL6 rearrangement was identified in 48% of NLPHL cases and was not detected in cHL cases. As a confirmation, sequential or simultaneous immunohistochemistry (IHC) and FISH using CD20 or BCL6 antibodies and BCL6 DNA probes was performed in 8 NLPHL cases. The BCL6-associated translocations, t(3;22)(q27;q11), t(3;7)(q27;p12), and the most probable t(3;9)(q27;p13), were identified in 3 cases. A consistent expression of BCL6 protein in popcorn cells with the highest number of intensely stained cells in cases with a genomic BCL6 rearrangement was shown by IHC. These findings support the hypothesis of a germinal center B cell-derived origin of NLPHL, indicate a significant role of BCL6 in the pathogenesis of NLPHL, and provide further evidence of the genetic diversity underlying the pathogenesis of NLPHL and cHL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393409     DOI: 10.1182/blood-2002-05-1592

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component.

Authors:  Tiemo Katzenberger; German Ott; Thomas Klein; Jörg Kalla; Hans Konrad Müller-Hermelink; M Michaela Ott
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

2.  Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.

Authors:  S Hartmann; B Schuhmacher; T Rausch; L Fuller; C Döring; M Weniger; A Lollies; C Weiser; L Thurner; B Rengstl; U Brunnberg; M Vornanen; M Pfreundschuh; V Benes; R Küppers; S Newrzela; M-L Hansmann
Journal:  Leukemia       Date:  2015-12-10       Impact factor: 11.528

3.  Molecular cytogenetic analyses of immunoglobulin loci in nodular lymphocyte predominant Hodgkin's lymphoma reveal a recurrent IGH-BCL6 juxtaposition.

Authors:  Christoph Renné; José Ignacio Martín-Subero; Martin-Leo Hansmann; Reiner Siebert
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

Review 4.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

5.  T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Stefania Pittaluga; Elaine S Jaffe
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

Review 6.  [Nodular lymphocyte-predominant Hodgkin's lymphoma and differential diagnoses].

Authors:  S Hartmann; S Cogliatti; M-L Hansmann
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

Review 7.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

8.  Utility of LRF/Pokemon and NOTCH1 protein expression in the distinction between nodular lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma.

Authors:  Olga Bohn; Takahiro Maeda; Alexander Filatov; Andrea Lunardi; Pier Paolo Pandolfi; Julie Teruya-Feldstein
Journal:  Int J Surg Pathol       Date:  2013-12-10       Impact factor: 1.271

Review 9.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

10.  Nodular lymphocyte-predominant hodgkin lymphoma or T-cell/histiocyte rich large B-cell lymphoma: the problem in "grey zone" lymphomas.

Authors:  Frank X Zhao
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.